Novel Therapeutic Approaches of Pulmonary Arterial Hypertension
Novel Therapeutic Approaches of Pulmonary Arterial Hypertension
复制标题
DOI：
10.1055/s-0039-1692140
复制
发表时间：
2019-06-01
影响因子：
0.6
通讯作者：
Batra, Vishal
中科院分区：
文献类型：
--
作者：
Tyagi, Sanjay;Batra, Vishal
肺动脉高压（PAH）是一种以肺血管进行性重构为特征的罕见疾病。虽然治疗多环芳烃的方法在过去二十年中有所改善，但结果仍然是致命的。目前，PAH的治疗针对三种成熟的途径：一氧化氮（NO）途径、内皮素受体和前列腺素。多环芳烃的新药开发有多种潜在靶点，需要细致的研究和临床试验。
Pulmonary arterial hypertension (PAH) is an uncommon disease characterized progressive remodeling of pulmonary vasculature. Although treatment for PAH have improved in last two decades but the outcome remains fatal. Currently, the therapies for PAH target three well-established pathways the nitric oxide (NO) pathway, endothelin receptors, and prostanoids. There are multiple potential targets for development of newer drugs in PAH which requires meticulous research and clinical trials.